Paper - WANFANG MED ONLINE

You Position: Home > Paper

Clinical value of inhibition of vascular endothelial growth factor in primary hepatocellular carcinoma after transcatheter arterial chemoembolization

( views:225, downloads:104 )

Author:: No author available

Journal Title:: WORLD CHINESE JOURNAL OF DIGESTOLOGY

Issue:: 15

DOI:: 10.3969/j.issn.1009-3079.2010.15.011

Key Word:: 血管内皮生长因子;原发性肝癌;动脉灌注;化疗栓塞

Abstract：血管内皮生长因子(vascular endothelial growth factor,VEGF)特异性地作用于血管内皮细胞,参与实体瘤血管的新生,并且与实体瘤的侵袭、转移等生物学行为密切相关.研究表明VEGF与原发性肝癌(primary hepatic carcinoma,PHC)的发生、发展及转移密切相关.经导管动脉灌注化疗栓塞(transcatheter arterical chemoembolization,TACE)近期疗效肯定,被广泛的应用于临床,成为PHC非手术疗法中的首选方法,但是,TACE远期疗效却并不理想.抑制VEGF和(或)VEGFR在PHC中的表达将会给PHC的治疗带来新的突破.本文复习文献,综述PHC介入治疗与VEGF的相关研究进展.

Reference

[1]卢武胜,李肖,王朝华,等.131I-HAb18F（ab'）2在肝癌病人体内的生物学分布[J].2003,(4).
[2]杜海军.重组人血管内皮抑素联合肝动脉灌注化疗栓塞治疗中晚期肝癌的临床应用[J].2009,(4).
[3]史跃,高从敬,董生良,等.细胞因子诱导杀伤细胞灌注治疗原发性肝癌临床应用[J].2007,(4).
[4]张芳杰,唐望先,吴翠环,等.缺氧诱导因子1α在肝癌中的表达及意义[J].2006,(4).
[5]郝明志,陈强,叶韵斌,等.肝动脉栓塞化疗联合CIK细胞疗法治疗原发性肝癌[J].2006,(4).
[6]赵建军,胡敬群,蔡建强,等.Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma[J].2003,(5).
[7]许国辉,张智慧,李政文,等.131 I肝癌单抗片段HAb18F（ab）2灌注治疗原发性肝癌的临床研究[J].2005,(6).
[8]顾宇,陆枫林.VEGF促进肝癌SMMC-7721细胞侵袭性的自分泌机制[J].2009,(32).
[9]李明意,姚金科,周晓华,等.MKK-4、MMP-9基因的表达与原发性肝癌肿瘤侵袭转移的关系[J].2006,(8).
[10]钱中清,曾耀英,王通,等.VEGF诱导血管内皮细胞产生H2O2及其促增殖作用[J].2007,(3).
[11]Lun-Xiu Qin,Zhao-You Tang.The prognostic molecular markers in hepatocellular carcinoma[J].2002,(3).
[12]周启明,吴沛宏,赵明,等.原发性肝癌经综合微创治疗后联合细胞因子诱导杀伤细胞灌注的近期疗效观察[J].2006,(11).
[13]封宇飞,雷静,傅得兴.血管内皮生长因子抑制剂--贝伐单抗[J].2005,(19).
[14]徐凯,罗海英,李柳宁,等.中药灌注栓塞为主综合治疗原发性肝癌的临床研究[J].2005,(4).
[15]Chun-hong MA,Yan Zhang,Xiao-Yan Wang,etc.Human endostatin gene transfer, either naked or with liposome, has the same inhibitory effect on growth of mouse liver tumor cells in vivo[J].2004,(19).
[16]李肖,官泳松,周翔平,等.20（R）-人参皂甙Rg3对大鼠肝癌细胞的作用[J].2005,(2).
[17]马立辉,周健,王助新,等.血清VEGF及CRP表达对肝细胞癌术后早期复发的预测[J].2009,(33).
[18]吴少平,卢武胜,徐大伟,等.肝癌DSA血供类型与经肝动脉灌注131Ⅰ-HAb18F（ab'）2治疗后瘤体大小变化的关系探讨[J].2007,(4).
[19]Zhong-Lin Zhang,Zhi-Su Liu,Quan Sun.Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma[J].2006,(26).
[20]陆运鑫,黄丁平,侯恩存,等.康艾注射液联合肝动脉栓塞化疗治疗原发性肝癌临床疗效观察[J].2007,(24).
[21]彭佳萍,郑树,孝作祥,等.Inducible nitric oxide synthase expression is related to angiogenesis, bcl-2 and cell proliferation in hepatocellular carcinoma[J].2003,(2).
[22]李兴睿,杨志芳,易继林.肝癌经肝动脉栓塞化疗后VEGF和CD44v6表达的意义[J].2006,(13).
[23]H, Yoshiji,S, Kuriyama,D J, Hicklin,etc.KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.[J].1999,30.
[24]Fujii H,An FQ,Matsuda M,etc.Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma.[J].2000,126(3).
[25]J, Holash,P C, Maisonpierre,D, Compton,etc.Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.[J].1999,284.
[26]Warakaulle D,Upponi S,Uberoi R,etc.Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology.[J].2008,19(5).
[27]Cristofori C,Baldan A,Sergio A,etc.Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.[J].2008,103(4).
[28]Boosani CS,Sudhakar A.Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression.[J].2008,25(12).
[29]Z, von Marschall,T, Cramer,M, H?cker,etc.Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma.[J].2001,48(1).
[30]Ana Paula, Elias,Sergio, Dias.Microenvironment changes (in pH) affect VEGF alternative splicing.[J].2008,1(1).
[31]Ernens I,Devaux Y,Vausort M,etc.Adenosine up-regulates vascular endothelial growth factor in human macrophages.[J].2010,392(3).
[32]Ueno Y,Kisara N,Kobayashi N,etc.Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization.[J].1999,19(1).
[33]Zhu AX,Sahani DV,Duda DG.Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.[J].2009,27(18).
[34]Gouw AS,Platteel I,Zhang N,etc.The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization.[J].2008,48(5).
[35]Melero I,Solano S,Hervas-Stubbs S,etc.Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.[J].2009,100(7).
[36]Sakurai S,Fujimori H,Yamamoto Y,etc.Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions.[J].1999,79(4).
[37]Nakamura K,Sato Y,Kozaka K,etc.Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1alpha are involved in malignant transformation in dysplastic nodules of the liver.[J].2007,38(10).
[38]Razny U,Dembinska Kiec A,Kiec Wilk B,etc.DNA methylation, induced by beta-carotene and arachidonic acid, plays a regulatory role in the pro-angiogenic VEGF-receptor (KDR) gene expression in endothelial cells.[J].2009,60(4).
[39]Lehrer D,Ocean A,Goldenberg A,etc.Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.[J].2008,26(18).
[40]Finn RS,Britten CD,Busuttil RW,etc.Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.[J].2009,29(2).
[41]Wang B,Xu H,Gao ZQ,etc.Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization.[J].2008,49(5).
[42]Liu D,Duchen MR,Bagherzadeh A,etc.Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells.[J].2004,279(34).
[43]Arai Y,Yamaura H,Miyazaki M,etc.Hepatic arterial infusion chemotherapy through a port-catheter system as preoperative initial therapy in patients with advanced liver dysfunction due to synchronous and unresectable liver metastases from colorectal cancer.[J].2008,31(1).
[44]Waterman Matthew,Karumanchi SAnanth,Sukhatme VikasP,etc.Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1.[J].2002,277(19).
[45]Yee KO,Lawler J,Kazerounian S.Thrombospondins in cancer[J].2008,65(5).
[46]Partho Sarothi Ray,Jie Jia,Mithu Majumder,etc.A Stress-responsive Rna Switch Regulates Vegfa Expression[J].2009,457(7231).
[47]Ian Zachary.Neuroprotective Role of Vascular Endothelial Growth Factor: Signalling Mechanisms, Biological Function, and Therapeutic Potential[J].2005,14(5).
[48]Byrne AM,Bouchier Hayes DJ,Harmey JH.Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).[J].2005,9(4).
[49]Ramanathan RK,Hsu CH,Tate WR,etc.The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.[J].2006,147(2).
[50]Yonemitsu Y.Vascular endothelial growth factor - basic science and its clinical implications.[J].2004,11(2).
[51]Pirjo Laakkonen,Reetta Peltonen,Maria Wirzenius,etc.Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation[J].2008,454(7204).
[52]D R, Senger,C A, Perruzzi,J, Feder,etc.A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.[J].1986,46.
[53].Discrepancies between antiangiogenic and antitumor effects of recombinant human endostatin.[J].2009,24(5).